Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.54 -2.7%	$9.79	$2.20 ▼ $12.78	$268.42M	-0.58	44,209 shs	24,781 shs
EDIT Editas Medicine	$2.73 +2.2%	$2.62	$0.91 ▼ $4.12	$240.09M	2.19	2.17 million shs	849,171 shs
LFCR Lifecore Biomedical	$7.22 -0.3%	$7.57	$3.68 ▼ $8.85	$270.83M	0.65	116,545 shs	55,639 shs
OVID Ovid Therapeutics	$0.96 +0.7%	$0.50	$0.24 ▼ $1.47	$67.55M	0.2	1.59 million shs	813,124 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	+1.07%	-0.35%	+3.95%	+12.60%	+117.03%
EDIT Editas Medicine	+1.52%	-13.31%	-15.24%	+64.81%	-32.58%
LFCR Lifecore Biomedical	-0.14%	-6.46%	-2.95%	+8.55%	+27.24%
OVID Ovid Therapeutics	+1.06%	+10.72%	+56.92%	+231.36%	-15.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.3118 of 5 stars	3.4	5.0	0.0	2.0	2.5	0.6
EDIT Editas Medicine	4.2136 of 5 stars	3.1	4.0	4.3	1.7	2.5	0.6
LFCR Lifecore Biomedical	1.4157 of 5 stars	2.3	0.0	0.0	1.9	4.2	0.6
OVID Ovid Therapeutics	4.2414 of 5 stars	3.6	3.0	4.6	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	54.61% Upside
EDIT Editas Medicine	2.23	Hold	$5.10	86.81% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	10.80% Upside
OVID Ovid Therapeutics	3.17	Buy	$3.10	223.93% Upside

Current Analyst Ratings Breakdown

Latest OVID, LFCR, DBVT, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $5.00
8/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $6.00
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$4.15M	62.96	N/A	N/A	$3.15 per share	3.03
EDIT Editas Medicine	$32.31M	7.60	N/A	N/A	$0.21 per share	13.00
LFCR Lifecore Biomedical	$128.87M	2.10	N/A	N/A	$0.04 per share	180.50
OVID Ovid Therapeutics	$570K	119.39	N/A	N/A	$0.78 per share	1.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.77	N/A	N/A	N/A	-3,220.49%	-287.15%	-138.83%	11/5/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$2.85	N/A	N/A	N/A	-608.88%	-200.25%	-68.57%	11/3/2025 (Estimated)
LFCR Lifecore Biomedical	-$38.72M	-$1.31	N/A	N/A	N/A	-31.70%	-846.51%	-13.03%	10/3/2025 (Estimated)
OVID Ovid Therapeutics	-$26.43M	-$0.53	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	N/A

Latest OVID, LFCR, DBVT, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	N/A	N/A	N/A	$35.36 million	N/A
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million
8/12/2025	Q2 2025	EDIT Editas Medicine	-$0.41	-$0.63	-$0.22	-$0.63	$1.81 million	$3.58 million
8/7/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	-$0.10	-$0.01	-$0.06	$35.36 million	$36.44 million
7/29/2025	Q2 2025	DBVT DBV Technologies	-$0.21	-$1.55	-$1.34	-$1.55	$0.64 million	$1.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	2.45	2.45
EDIT Editas Medicine	N/A	2.77	2.77
LFCR Lifecore Biomedical	113.76	2.84	1.77
OVID Ovid Therapeutics	0.23	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
EDIT Editas Medicine	71.90%
LFCR Lifecore Biomedical	83.36%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
EDIT Editas Medicine	2.10%
LFCR Lifecore Biomedical	32.20%
OVID Ovid Therapeutics	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
EDIT Editas Medicine	230	89.92 million	88.03 million	Optionable
LFCR Lifecore Biomedical	690	37.41 million	25.36 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable

OVID, LFCR, DBVT, and EDIT Headlines

Recent News About These Companies

Spotlight On 3 Promising Penny Stocks With Over $60M Market Cap

August 20 at 7:34 PM | uk.finance.yahoo.com

William Blair Has Positive Forecast for OVID FY2025 Earnings

August 19 at 3:03 AM | americanbankingnews.com

William Blair Predicts Higher Earnings for Ovid Therapeutics

August 19 at 2:59 AM | marketbeat.com

Ovid Therapeutics (NASDAQ:OVID) Raised to "Hold" at Wall Street Zen

August 19 at 2:27 AM | americanbankingnews.com

Q3 EPS Estimates for Ovid Therapeutics Increased by B. Riley

August 19 at 2:56 AM | marketbeat.com

Wedbush Research Analysts Lower Earnings Estimates for OVID

August 19 at 2:56 AM | marketbeat.com

B. Riley Increases Earnings Estimates for Ovid Therapeutics

August 19 at 2:45 AM | americanbankingnews.com

Ovid Therapeutics (NASDAQ:OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

August 17, 2025 | marketbeat.com

Ovid Therapeutics (NASDAQ:OVID) Rating Increased to Hold at Wall Street Zen

August 17, 2025 | marketbeat.com

Ovid Therapeutics Second Quarter 2025 Earnings: Beats Expectations

August 16, 2025 | finance.yahoo.com

Brokerages Set Ovid Therapeutics (NASDAQ:OVID) PT at $3.10

August 16, 2025 | americanbankingnews.com

Ovid Therapeutics Reports Increased Revenue Amid Challenges

August 14, 2025 | msn.com

Ovid Therapeutics Navigates FDA Disruptions and Government Challenges

August 14, 2025 | tipranks.com

Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating

August 13, 2025 | tipranks.com

Ovid Therapeutics initiated with a Buy at Lucid Capital

August 13, 2025 | msn.com

Ovid Therapeutics Transfers Stock to Nasdaq Capital Market

August 13, 2025 | msn.com

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

August 13, 2025 | globenewswire.com

Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating

August 13, 2025 | investing.com

Amit Rakhit: Global Access, Local Wisdom — How Biotech Thrives Amid Regulatory Complexity

August 13, 2025 | msn.com

Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OVID, LFCR, DBVT, and EDIT Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.87 +0.07 (+0.71%)

As of 04:00 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Editas Medicine NASDAQ:EDIT

$2.73 +0.06 (+2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$2.74 +0.01 (+0.22%)

As of 07:47 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Lifecore Biomedical NASDAQ:LFCR

$7.22 -0.02 (-0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$7.20 -0.01 (-0.21%)

As of 04:20 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Ovid Therapeutics NASDAQ:OVID

$0.96 +0.01 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 -0.04 (-3.76%)

As of 07:55 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time